Compare CERT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | CMPX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 1576 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 978.7M | 927.5M |
| IPO Year | 2020 | 2020 |
| Metric | CERT | CMPX |
|---|---|---|
| Price | $6.39 | $5.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $12.22 | ★ $14.43 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 05-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | N/A |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $5.40 | $677.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $6.04 | $1.33 |
| 52 Week High | $15.38 | $6.88 |
| Indicator | CERT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 34.85 |
| Support Level | $6.04 | $4.86 |
| Resistance Level | $7.52 | $5.86 |
| Average True Range (ATR) | 0.32 | 0.28 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 24.33 | 9.09 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.